LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that J. Thomas Megerian, M.D., Ph.D., executive director for clinical development at EPIX, is scheduled to participate in a session entitled, “Strategy for Trial Design for Treatments with Potential Symptomatic and Disease Modifying Effects: Program Development Issues II” at the Alzheimer’s Association Research Roundtable: Optimal Trial Design for Disease Modifying Therapies in Alzheimer’s Disease meeting in Washington, D.C., on Tuesday, October 21, 2008 at 9:30 a.m. (ET).
